Bevacizumab and Erlotinib
Sponsors
University of Utah, Duke University
Conditions
CancerGlioblastomaGliosarcoma
Phase 2
Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
CompletedNCT00585377
Start: 2007-08-31End: 2013-05-31Updated: 2015-09-24
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
CompletedNCT00671970
Start: 2007-02-28End: 2010-04-30Updated: 2013-05-13